FORMOSA PHARMACEUTICALS , INC

 

Area: Pharmaceutical and Medical Devices

Booth No: L424

Website: https://www.formosapharma.com

 

Exhibitor Profile

 

Formosa Pharmaceuticals, founded in 2010, is a late-preclinical and clinical stage biotechnology company with assets in ophthalmology, oncology, and anti-infectives.
Our Business Interests:
Seeking out-licensing or co-development opportunities for assets and technology.
* APP13007 (Ophthalmic Nanosuspension for Inflammation and Pain after Ocular Surgery) [under US FDA review]
* TSY-0110 (ADC biosimilar of Kadcyla (T-DM1)) [Late-preclinical stage]
* APNT Nanoparticle Formulation Platform

 

Brands

 

APP13007, TSY-0110, APP13002, APNT platform

 

Video

 

• 

  APNT Nanoparticle Formulation Platform & APP13007 Nanosuspension

 

 

Exhibit Products

 

• 

  APP13002 - Infectious Eye Diseases Treatment

• 

  APP13007 - ophthalmic eyedrop for post-surgical ocular pain and inflammation

• 

  APNT Nanoparticle Formulation Platform

• 

  TSY-0110 - Kadcyla Biosimilar

 

Exhibitor Press Release

 

• Formosa Pharmaceuticals Announce FDA Acceptance Of NDA Filing For APP13007 2023-07-11
• Formosa Pharmaceuticals Announces Development Collaboration Agreement With Eyenovia 2023-05-08
• Formosa Pharmaceuticals Announce The NDA Submission To The US FDA For APP13007 2023-05-08

 

 

 

back